医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market

2018年09月12日 PM09:31
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the U.S. Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had U.S. sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.

Dr. Reddy’s Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 mL and 10 mg/10 mL multi-dose vials.

Please click here for full Prescribing Information.

Bloxiverz is a registered trademark of Avadel Legacy Pharmaceuticals LLC.

*IMS National Sales Perspective: Retail and Non-Retail MAT July 2018
RDY-0918-212

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005597/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK SAVLA
Ph:
+91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS
CALVIN PRINTER
Ph: +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • UNITE HERE Cautions FDA Over Chinese Pharmaceutical Giant’s Purchase of Stake in GNC
  • HIMSS宣布 Healthcare IT News和MobiHealth News的国际扩张
  • 武田宣布就拟议的夏尔收购事宜发布宣传册和特别股东大会通知
  • Gi-Won Plus Ltd. Introduces “Bebettirang G8″, an All in One Hipseat Baby Carrier
  • Gi-Won Plus Ltd.が一体型ヒップシートベビーキャリアの”Bebettirang G8″を発表